There are a growing number of patients who require additional treatment for spinal muscular atrophy, after receiving Zolgensma, a gene therapy costing $1.9 million and developed by Novartis in 2019, doctors are reporting.
This could be due to up to 15-20 percent of children who receive the treatment potentially having antibodies to the vector used, Reuters reported.